Clinical Trial Detail

NCT ID NCT04212013
Title A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

marginal zone B-cell lymphoma

Therapies

Ibrutinib

Ibrutinib + Rituximab

Age Groups: adult senior

No variant requirements are available.